Cargando…
Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics
Mycobacterium tuberculosis (Mtb) has recently surpassed HIV/AIDS as the leading cause of death by a single infectious agent. The standard therapeutic regimen against tuberculosis (TB) remains a long, expensive process involving a multidrug regimen, and the prominence of multidrug-resistant (MDR), ex...
Autores principales: | Biecker, Ashley L., Liu, Xiaodong, Thorson, Jon S., Yang, Zhaoyong, Van Lanen, Steven G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384614/ https://www.ncbi.nlm.nih.gov/pubmed/30691073 http://dx.doi.org/10.3390/molecules24030433 |
Ejemplares similares
-
An orthogonal and reactivity-based one-pot glycosylation strategy for both glycan and nucleoside synthesis: access to TMG-chitotriomycin, lipochitooligosaccharides and capuramycin
por: He, Haiqing, et al.
Publicado: (2021) -
Site-Specific Modification of the Anticancer and Antituberculosis Polyether Salinomycin by Biosynthetic Engineering
por: Luhavaya, Hanna, et al.
Publicado: (2014) -
Characterization of the Ohmyungsamycin Biosynthetic Pathway and Generation of Derivatives with Improved Antituberculosis Activity
por: Kim, Eunji, et al.
Publicado: (2019) -
Discovery of a capuramycin analog that kills non-replicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors
por: Siricilla, Shajila, et al.
Publicado: (2014) -
Pyridoxal-5′-Phosphate-Dependent Alkyl Transfer in Nucleoside Antibiotic Biosynthesis
por: Cui, Zheng, et al.
Publicado: (2020)